Current treatment options for colon cancer peritoneal carcinomatosis

被引：82

作者：

Aoyagi, Tomoyoshi ^{[1
]}

Terracina, Krista P. ^{[1
]}

Raza, Ali ^{[1
]}

Takabe, Kazuaki ^{[1
]}

机构：

[1] Virginia Commonwealth Univ, Sch Med, Dept Surg, Div Surg Oncol, Richmond, VA 23298 USA

来源：

WORLD JOURNAL OF GASTROENTEROLOGY | 2014年 / 20卷 / 35期

关键词：

Cancer; Colorectal; Carcinomatosis; Peritoneal; hyperthermic intraperitoneal chemotherapy; Intraperitoneal chemotherapy; Cytoreductive surgery; Mechanism; HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY; METASTATIC COLORECTAL-CANCER; HUMAN MESOTHELIAL CELLS; PHASE-III TRIAL; CYTOREDUCTIVE SURGERY; SYSTEMIC CHEMOTHERAPY; ADHESION MOLECULES; INFLAMMATORY CYTOKINES; ANTIBODY CATUMAXOMAB; SURFACE MALIGNANCY;

D O I：

10.3748/wjg.v20.i35.12493

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

100201 [内科学];

摘要：

Peritoneal carcinomatosis (PC), the dissemination of cancer cells throughout the lining of the abdominal cavity, is the second most common presentation of colon cancer distant metastasis. Despite remarkable advances in cytotoxic chemotherapy and targeted therapy for colon cancer over the last 15 years, it has been repeatedly shown that these therapies remain ineffective for colon cancer PC. Recently, there has been a rapid accumulation of reports that cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) prolongs the life of colon cancer PC patients. Here, we will review the clinical presentation, the mechanisms of disease progression, and current treatment options for colon cancer PC, with a focus on the benefits and limitations of CRS-HIPEC. (C) 2014 Baishideng Publishing Group Inc. All rights reserved.

引用

页码：12493 / 12500

页数：8

共 83 条

[1]

ABUHIJLEH MF, 1995, J ANAT, V186, P453

[2]

Current status and future strategies of cytoreductive surgery plus intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis [J].